Peter BillingsleyFred BinkaCarlos ChaccourBrian D. FoySilvia GoldMatiana Gonzalez-SilvaJulie JacobsonGeorge JagoeCaroline JonesPatrick KachurKevin KobylinskiAnna LastJames V. LaveryDavid MabeyLeonard MboeraCharles MbogoAna Mendez-LopezN. Regina RabinovichSarah ReesFrank RichardsCassidy RistJessica RockwoodPaula Ruiz-CastilloJetsumon SattabongkotFrancisco SauteHannah SlaterAndrew SteerKang XiaRose ZulligerUniversity of Health and Allied Sciences, GhanaSanaria Inc.Instituto de Salud Global de BarcelonaIfakara Health InstituteWellcome Trust Research Laboratories NairobiUniversidad de NavarraHarvard T.H. Chan School of Public HealthLondon School of Hygiene & Tropical MedicineColumbia University in the City of New YorkVirginia Polytechnic Institute and State UniversityUniversity of MelbourneCenters for Disease Control and PreventionArmed Forces Research Institute of Medical Sciences, ThailandVirginia-Maryland College of Veterinary MedicineMahidol UniversityColorado State UniversityEmory UniversityInternational Public Health AdvisorsBridges to DevelopmentMedicines for Malaria VentureSACIDS Foundation for One HealthFundación Mundo SanoInnovative Vector Control ConsortiumThe Carter CenterPATHCentro de Investigação em Saúde da Manhiça (CISM)2020-05-052020-05-052020-01-01American Journal of Tropical Medicine and Hygiene. Vol.102, (2020), 3-24000296372-s2.0-85079102482https://repository.li.mahidol.ac.th/handle/123456789/54587Copyright © 2020 by The American Society of Tropical Medicine and Hygiene. In the context of stalling progress against malaria, resistance of mosquitoes to insecticides, and residual transmission, mass drug administration (MDA) of ivermectin, an endectocide used for neglected tropical diseases (NTDs), has emerged as a promising complementary vector control method. Ivermectin reduces the life span of Anopheles mosquitoes that feed on treated humans and/or livestock, potentially decreasing malaria parasite transmission when administered at the community level. Following the publication by WHO of the preferred product characteristics for endectocides as vector control tools, this roadmap provides a comprehensive view of processes needed to make ivermectin available as a vector control tool by 2024 with a completely novel mechanism of action. The roadmap covers various aspects, which include 1) the definition of optimal dosage/regimens for ivermectin MDA in both humans and livestock, 2) the risk of resistance to the drug and environmental impact, 3) ethical issues, 4) political and community engagement, 5) translation of evidence into policy, and 6) operational aspects of large-scale deployment of the drug, all in the context of a drug given as a prevention tool acting at the community level. The roadmap reflects the insights of a multidisciplinary group of global health experts who worked together to elucidate the path to inclusion of ivermectin in the toolbox against malaria, to address residual transmission, counteract insecticide resistance, and contribute to the end of this deadly disease.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.4269/ajtmh.19-0620